Sonnet BioTherapeutics’ Public Offering: 2.84 Million Shares at $1.60 Each, Totaling $4.55M – Shares Decline
In a significant stride towards advancing targeted biologic drugs, clinical-stage company Sonnet BioTherapeutics Holdings unveiled today the pricing details of its underwritten public offering. This
